May reduce mental fatigue and support cognitive health (especially helpful with GLP-1 fatigue)
Half-life is the amount of time it takes for the drugs initial concentration in the body to decrease by half
However, it did not yield significant improvements in pain perception.[64] GLP-1 receptors have also been detected in the choroid plexus, and in a rodent model, their activation was shown to reduce cerebrospinal fluid secretion and intracranial pressure (ICP).[65] In patients with idiopathic intracranial hypertension (IIH) and obesity, exenatide, semaglutide, liraglutide have been associated with a reduction in the number of headache days, and exenatide significantly reduced ICP.[66, 67] Furthermore, animal studies have indicated potential benefits of GLP-1RAs in neuropathic pain and diabetic neuropathy, although clinical evidence remains inconsistent.[64] One study reported structural improvements in the nerves of patients with diabetic neuropathy receiving semaglutide or dulaglutide, while two other studies found no significant benefit in neuropathy symptoms with liraglutide and exenatide.[6870] Additional off-label uses under investigation include neurodegenerative disorders, polycystic ovary syndrome (PCOS), and osteoporosis
Cant sleep
Transplanting the microbiome from an obese twin drives obesity
